
FDA Recommends Against Seven Peptides for the 503A Bulks List: What Compounders, Clinics, and Peptide Sellers Need to Know About Federal Exposure
The FDA just recommended against adding BPC-157, TB-500, and five more peptides to the 503A list. If you compound or sell them, know your federal exposure now.












